Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known which regimen of combination chemotherapy is more effective for Hodgkin lymphoma.

PURPOSE: This phase II trial is studying the side effects of three different regimens of combination chemotherapy and to see how well they work in treating younger patients with Hodgkin lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University College, London
• Treatments: Cyclophosphamide; Doxorubicin; Etoposide; Etoposide phosphate; Liposomal doxorubicin; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Procarbazine; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Biopsy proven de-novo classical Hodgkin lymphoma

• Any stage disease

• No nodular lymphocyte-predominant Hodgkin lymphoma

PATIENT CHARACTERISTICS:

• No known or suspected HIV infection

• No pre-existing neurological disorder

• No serious comorbidity which may prevent administration of study treatment

• No other previous malignancy

• Not pregnant or nursing

• Fertile patients must use effective contraception during and for up to 1 year after completion of study treatment

• Creatinine ≤ 1.5 times upper limit of normal (ULN) unless due to the lymphoma

• ALT/AST ≤ 1.5 times ULN unless due to the lymphoma

• Bilirubin ≤ 2 times ULN unless due to the lymphoma

PRIOR CONCURRENT THERAPY:

• No prior chemotherapy or radiotherapy

• No prior organ transplant